EP300 and acute lymphoblastic leukemia: In contrast to other reports where ZNF384 fusions have multiple 5′ partners, we exclusively detected EP300-ZNF384 fusions in 5.7% of BCR-ABL1-negative AYA/adult pre-B-ALL, making it one of the more prevalent recurrent lesions in this age group.